Akebia Therapeutics (AKBA) Free Cash Flow Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Free Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | 44.93% |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | -61.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.38% |
| Dec 31, 2025 | 853.42% |
| Sep 30, 2025 | 490.47% |
| Jun 30, 2025 | 346.85% |
| Mar 31, 2025 | 32.13% |
| Dec 31, 2024 | -164.99% |
| Sep 30, 2024 | 53.21% |
| Jun 30, 2024 | -239.75% |
| Mar 31, 2024 | 1.50% |
| Dec 31, 2023 | 110.73% |
| Sep 30, 2023 | -164.79% |
| Jun 30, 2023 | 126.17% |
| Mar 31, 2023 | -15.27% |
| Dec 31, 2022 | 12.94% |
| Sep 30, 2022 | 139.15% |
| Jun 30, 2022 | 59.22% |
| Mar 31, 2022 | 74.56% |
| Dec 31, 2021 | -132.25% |
| Sep 30, 2021 | -78.87% |
| Jun 30, 2021 | -262.10% |